PYPD Earnings Prediction
The chart below shows how PYPD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PYPD sees a +6.58% change in stock price 10 days leading up to the earnings, and a +0.03% change 10 days following the report. On the earnings day itself, the stock moves by -3.71%. This data can give you a slight idea of what to expect for the next quarter's release.
PYPD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-1.13
-68.87%
-7.38%
No Data Available
PYPD Earnings Analysis
PolyPid Ltd Corporation (PYPD.O) Earnings Conference Call
Positive
Trial Conclusion Recommendation: Recommendation by the Independent Data Safety Monitoring Board to conclude the SHIELD II Phase III trial upon enrollment of 800 patients, indicating positive efficacy signals for DPLEX-one hundred.
Private Placement Financing Completion: Completion of a private placement financing for $14,500,000 in gross proceeds, extending cash runway into the third quarter of 2025, beyond expected top line results from SHIELD II.
Market Potential Analysis: The total addressable market for DPLEX-one hundred in the U.S. is estimated at over 12 million surgeries annually, highlighting significant commercial potential.
Cash Reserves and Funding: The company had cash and cash equivalents of $15,600,000 as of December 31, 2024, ensuring sufficient funding for operations into the third quarter of 2025.
Partnership Opportunities Increase: Active discussions with potential partners for commercialization have increased following the DSMB recommendation, indicating a positive shift in partnership opportunities.
Negative
R&D Expense Increase: Research and development expenses for Q4 2024 were $7,000,000, up from $4,600,000 in Q4 2023, indicating a significant increase in costs associated with the ongoing SHIELD II Phase III trial.
Net Loss Comparison: The company reported a net loss of $8,500,000 for Q4 2024, compared to a net loss of $6,400,000 in Q4 2023, reflecting worsening financial performance year-over-year.
Increasing Net Losses: For the full year 2024, the net loss was $29,000,000, an increase from a net loss of $23,900,000 in 2023, highlighting a trend of increasing losses.
Trial Sample Size Concerns: The SHIELD II trial's sample size was reduced to 800 patients, which may raise concerns about the robustness of the trial results and the overall efficacy of DPLEX-one hundred.
Surgical Site Infection Increase: A CDC report indicated a 3% increase in surgical site infections (SSIs) across all surgeries in 2023 compared to 2022, suggesting a challenging market environment for DPLEX-one hundred.
PYPD FAQs
How does PYPD typically perform around its earnings report dates?
Is PolyPid Ltd (PYPD) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PYPD Earning Call Sentiment
Earnings call transcript: PolyPid Q4 2024 reports widening net loss, stock dips
PYPD.O
1%Positive
The earnings call reveals financial pressures, with increasing net losses and R&D expenses. The company faces regulatory and market competition risks, and management's unclear responses in the Q&A raise concerns. While there is potential for additional funding through warrant exercises, the lack of positive guidance and competitive market challenges suggest a negative stock price movement. The absence of a new partnership announcement and no significant positive catalysts further support a negative sentiment.
